These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28759760)

  • 21. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
    Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
    Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.
    Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM
    J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin.
    Mitsuguro M; Okamoto A; Shironouchi Y; Sano M; Miyata S; Neki R; Araki T; Hamamoto T; Yoshimatsu J; Miyata T
    Int J Hematol; 2015 Feb; 101(2):119-25. PubMed ID: 25416968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin].
    Mariné L; Sánchez G; Vargas JF; Zúñiga P; Aizman A; Mertens R; Bergoeing M; Muñoz B
    Rev Med Chil; 2014 Nov; 142(11):1392-7. PubMed ID: 25694284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis.
    Shinoda T; Arakura H; Katakura M; Shirota T; Nakagawa S
    Artif Organs; 1990 Dec; 14(6):413-5. PubMed ID: 2177970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
    Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.
    Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM
    J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
    Frugé KS; Lee YR
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Time Within Therapeutic Range Using Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children.
    Haftmann RJ; Pineda EM; Hall BA; Wilson MD; Mateev SN
    J Pediatr Pharmacol Ther; 2023; 28(3):228-234. PubMed ID: 37303766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis.
    Swayngim R; Preslaski C; Burlew CC; Beyer J
    Thromb Res; 2021 Dec; 208():18-25. PubMed ID: 34678527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance Between Active Partial Thromboplastin Time and Anti-Factor Xa Assays in Neurocritically Ill Patients Receiving Subcutaneous Heparin Prophylaxis.
    Shinn G; Berger K; Roh D; Doyle K; Boehme AK; Connolly ES; Park S; Agarwal S; Claassen J; Der-Nigoghossian C
    Neurohospitalist; 2023 Jul; 13(3):221-227. PubMed ID: 37441213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
    Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
    Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.
    Toulon P; Smahi M; De Pooter N
    J Thromb Haemost; 2021 Aug; 19(8):2002-2006. PubMed ID: 33555096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes.
    Toulon P; Appert-Flory A; Fischer F; Buvat S; Jambou D; Mahagne MH
    Thromb Res; 2020 Feb; 186():7-12. PubMed ID: 31837560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Overview of Heparin Monitoring with the Anti-Xa Assay.
    Dean CL
    Methods Mol Biol; 2023; 2663():343-353. PubMed ID: 37204722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.